SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-018170
Filing Date
2024-05-08
Accepted
2024-05-08 08:35:37
Documents
15
Period of Report
2024-05-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45756
2 ex99-1.htm EX-99.1 18618
3 ex99-1_001.jpg GRAPHIC 5387
  Complete submission text file 0001493152-24-018170.txt   252136

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT anix-20240503.xsd EX-101.SCH 3006
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT anix-20240503_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT anix-20240503_pre.xml EX-101.PRE 22353
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3697
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 24924401
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)